Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and
represents the hepatic expression of several metabolic abnormalities of high epidemiologic …

Background & Aims EDP-305 is an oral farnesoid X receptor (FXR) agonist under
development for treating nonalcoholic steatohepatitis (NASH). The efficacy, safety, and …

The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed
in liver and intestine, regulates the expression of genes involved in cholesterol and bile acid …

Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and this
nomenclature MAFLD was proposed to renovate its former name, non-alcoholic fatty liver …

Cholangiopathies encompass various biliary diseases affecting the biliary epithelium,
resulting in cholestasis, inflammation, fibrosis, and ultimately liver cirrhosis. Primary biliary …

Introduction: Non-alcoholic fatty liver disease (NAFLD) incidence has been rapidly
increasing, and it has emerged as one of the major diseases of the modern world. NAFLD …

The farnesoid X receptor (FXR) is a ligand-activated nuclear receptor. Activation of FXR
significantly impacts the expressions of the pivotal genes involved in bile acid metabolism …